Biogen has partnered with NeuroSense Therapeutics to conduct a study on the effects of PrimeC on neurofilament levels in patients with ALS. The study will be funded by Biogen and use blood samples from 69 PARADIGM patients provided by NeuroSense. The collaboration includes data sharing and joint evaluation of correlations among endpoints. PrimeC is an investigational combination therapeutic composed of two FDA-approved drugs, ciprofloxacin and celecoxib, designed to slow ALS progression, ease inflammation in neurons, and mitigate their degeneration.
NeuroSense released pharmacokinetic data for PrimeC in September 2022, which demonstrated that the candidate was safe and could simultaneously release ciprofloxacin and celecoxib when taken. This pharmacokinetic profile could help the Israel biotech design and launch a pivotal Phase III ALS study in the U.S. As part of Tuesday’s collaboration, Biogen will also receive a right of first refusal for any potential licensing agreement to co-develop and commercialize PrimeC.
The partnership follows Biogen's regulatory victory for Qalsody (tofersen) for treating super